WASHINGTON – After headlines emerged Wednesday about new data linking prolonged bisphosphonate use to an increased risk of atypical femur fractures, the FDA rushed to assure prescribers and the public that the agency has yet to find a clear connection.
Continue reading here:
FDA: No Clear Evidence Linking Bisphosphonates and Fractures (BioWorld)
BERKELEY, Calif. — XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the full year and fourth quarter of 2009 and provided a general business update.
Originally posted here:
XOMA Reports 2009 and Fourth Quarter Financial Results (GlobeNewswire via Yahoo! Finance)
LINCOLNSHIRE, Ill.—-BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia patients taking the drug Gleevec .
See original here:
BioSante Announces Positive Leukemia Vaccine Results (Business Wire via Yahoo! Finance)
Vietnam’s pharmaceutical market was valued at around VND27,265bn (US$1.53bn) in 2009. Over the next five years, we forecast that the market should grow at a compound annual growth rate (CAGR) of 15.8% in local currency terms to reach a value of VND56,706bn (US$3.29bn) in 2014. Our long-range forecast is for the market to reach VND89,509bn (US$6.07bn) in 2019, equating to a CAGR of 12.6%. Our …
View original post here:
Vietnam Pharmaceuticals And Healthcare Report Q2 2010 – New Market Report Published (OfficialWire)
CEL-SCI Corporation announced today that it has received a $125,000 payment from Byron Biopharma under its licensing agreement where CEL-SCI granted Byron an exclusive license to market and distribute the Company’s cancer drug Multikine® in the Republic of South Africa .
View original post here:
CEL-SCI Receives Payment From Marketing Partner (PR Newswire via Yahoo! Finance)
LINCOLNSHIRE, Ill.—-BioSante Pharmaceuticals, Inc. today announced the closing of the sale, directly to funds affiliated with two institutional investors, of an aggregate of approximately 10.4 million shares of BioSante’s common stock and warrants to purchase up to approximately 5.2 million shares of its common stock, resulting in gross cash proceeds to BioSante of $18 million.
Columbia Laboratories, Inc. has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of certain progesterone products. Additional payments up to $45.5 million can be earned by the successful …
Continued here:
Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals (News-Medical-Net)
Intas Pharmaceutical to Launch Phase 3 Clinical Trial in India to Test Amarillo Biosciences’ Oral Interferon Against Influenza
AMARILLO, TX–(Marketwire – 03/04/10) – Amarillo Biosciences, Inc. (ABI) (OTC.BB: AMAR – News ) today announced that it has executed a license and supply agreement with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India. Intas plans to launch a double-blind, placebo-controlled Phase 3 clinical trial of ABI’s orally administered interferon-alpha lozenges in …
See the article here:
Amarillo Biosciences and Intas Pharmaceuticals Sign License and Supply Agreement to Use Oral Interferon to Treat … (Marketwire via Yahoo! Finance)
LINCOLNSHIRE, Ill.—-BioSante Pharmaceuticals, Inc. today announced that it has received commitments from two institutional investors to purchase $18 million of securities in a registered direct offering.
Read this article:
BioSante Pharmaceuticals to Raise $18 Million in Registered Direct Offering (Business Wire via Yahoo! Finance)